Inhibition of tryptophan-dioxygenase activity increases the antitumor efficacy of immune checkpoint inhibitors

Tryptophan 2,3-dioxygenase (TDO) is an enzyme that degrades tryptophan into kynurenine and thereby induces immunosuppression. Like indoleamine 2,3-dioxygenase (IDO1), TDO is considered as a relevant drug target to improve the efficacy of cancer immunotherapy. However, its role in various immunothera...

詳細記述

書誌詳細
主要な著者: Schramme, F, Crosignani, S, Frederix, K, Hoffmann, D, Pilotte, L, Stroobant, V, Preillon, J, Driessens, G, Van Den Eynde, B
フォーマット: Journal article
言語:English
出版事項: American Association for Cancer Research 2019

類似資料